abugarciablackmax3castingreel| Hot View Bio: Joint-stock company SGC001 innovative drug research and development clinical trial application was approved by the FDA

News summary

[Hot View Bio: Joint-stock company SG001 innovative drug research and development clinical trial application approved by FDA] Securities Times e Company Newsabugarciablackmax3castingreel, Rejing Biotech (688068) announced on the evening of May 27. Recently, the company received a letter of notification from its shareholding company Shunjing Pharmaceutical that the innovative drug SGC001 developed by Shunjing Pharmaceutical isabugarciablackmax3castingreel...

Newsletter text

[Rejing Biotech: Participating company SGC001 clinical trial application for innovative drug research and development received FDA approval] Securities Times e Company News, Rejing Biotech (688068) announced on the evening of May 27 that the company recently received a notice from participating company Shunjing Pharmaceutical. Letter, the innovative drug SGC001 developed by Shunjing Pharmaceutical has been approved by the U.S. Food and Drug Administration (FDA). SGC001 is a monoclonal antibody drug for emergency use jointly developed by the R & D team of Professor Sun Zhiwei of Shunjing Medicine and the team of Professor Du Jie of the Beijing City Institute of Cardiopulmonary and Vascular Diseases of Capital Medical University. It is suitable for emergency treatment of patients with acute myocardial infarction.